Reduced expression of desmoglein-2 (DSG2) in SSc-MVECs was one of the most striking differences, as demonstrated by differential transcriptome profiling and by immunohistochemistry of endothelial cells (EC) performed in patients affected by the diffuse form of SSc [3]. The gene discussed is DSG2; the disease is systemic sclerosis.